BackAvenue Therapeutics Overview

Avenue Therapeutics Other Assets

Track Avenue Therapeutics's other assets ($34K) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Other Assets
$34000.00

Peer trimmed avg / median

Loading

Avenue Therapeutics Other Assets History

Loading

Avenue Therapeutics vs. peers: Other Assets Comparison

Loading

Avenue Therapeutics Other Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Avenue Therapeutics (ATXI) FAQ

As of the most recent data (June 2026), ATXI shows a other assets of $34K. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ATXI's other assets is now $34K (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Avenue Therapeutics is outperforming or lagging.

Tracking ATXI's other assets over time shows whether Avenue Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $34K In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this other assets page, Stockcircle has Avenue Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect other assets (currently $34K) with ownership activity and broader fundamentals.

Avenue Therapeutics's other assets is $34K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.